Non-Hodgkin lymphoma market to grow to $9.2 billion

The non-Hodgkin lymphoma (NHL) market will be worth $9.2 billion by 2020, according to new research.

This is up from $5.6 billion in 2013 at a modest compound annual growth rate (CAGR) of 7.4%. This growth will be driven by the expected launch of promising drugs, including novel small molecule inhibitors and next-generation monoclonal antibodies, as well as the continued use of the current blockbuster, Roche’s Rituxan/Mabthera (rituximab).

The launch of a premium-priced novel glycol-engineered antibody; obinutuzumab; the personalized vaccine dasiprotimut-T, mTOR inhibitor everolimus, and several kinase inhibitors including Gilead Sciences’ Zydelig (idelalisib) and Imbruvica (ibrutinib) from Pharmacyclics/Janssen Biotech (which gained US Food and Drug Administration approval in July) are expected to have a significant impact on the market size.